Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-12

AUTHORS

Joachim Beck, Joaquim Bellmunt, Bernard Escudier

ABSTRACT

Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported. A 66-year-old man was diagnosed with advanced RCC in 2005. The patient initially underwent nephrectomy, but subsequently the disease metastasized to the lung, lymph nodes, and pancreas. The patient received sorafenib 400 mg bid in a clinical trial. He experienced minimal and manageable adverse events and achieved stable disease (SD), which was maintained with sorafenib therapy for nearly 3 years before the development of liver metastases. The patient was then prescribed sunitinib, with which he also experienced SD for 1.2 years until disease progression prompted the initiation of third-line everolimus therapy, resulting in SD for another 8 months. The patient lived with stabilized RCC for 4.6 years with the use of these three sequential targeted therapies. First-line sorafenib monotherapy achieved a durable stable response and subsequent use of sunitinib and then everolimus permitted a return to SD after disease progression. The patient experienced minimal toxicity from the regimen, suggesting that it can be safely administered to elderly patients. More... »

PAGES

1379-1383

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-010-9589-x

DOI

http://dx.doi.org/10.1007/s12032-010-9589-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1030799862

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20593250


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzenesulfonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase II as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphatic Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sirolimus", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Johannes Gutenberg University of Mainz", 
          "id": "https://www.grid.ac/institutes/grid.5802.f", 
          "name": [
            "Internal Department III, Johannes-Gutenberg-University, Langenbeckstr. 1, 55131, Mainz, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beck", 
        "givenName": "Joachim", 
        "id": "sg:person.010707011202.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010707011202.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Del Mar", 
          "id": "https://www.grid.ac/institutes/grid.411142.3", 
          "name": [
            "Department of Oncology, University Hospital del Mar-IMIM, 08003, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bellmunt", 
        "givenName": "Joaquim", 
        "id": "sg:person.01174264563.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174264563.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.juro.2009.02.119", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001110310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2006.06015.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002209252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2006.06015.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002209252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.1293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013684571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djn319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015009768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.3342", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015052000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24241", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015298784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24241", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015298784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.07.960", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015578863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.5511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017988502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2008.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041881420"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.23.16_suppl.3069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079369106"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-12", 
    "datePublishedReg": "2011-12-01", 
    "description": "Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported. A 66-year-old man was diagnosed with advanced RCC in 2005. The patient initially underwent nephrectomy, but subsequently the disease metastasized to the lung, lymph nodes, and pancreas. The patient received sorafenib 400\u00a0mg bid in a clinical trial. He experienced minimal and manageable adverse events and achieved stable disease (SD), which was maintained with sorafenib therapy for nearly 3\u00a0years before the development of liver metastases. The patient was then prescribed sunitinib, with which he also experienced SD for 1.2\u00a0years until disease progression prompted the initiation of third-line everolimus therapy, resulting in SD for another 8\u00a0months. The patient lived with stabilized RCC for 4.6\u00a0years with the use of these three sequential targeted therapies. First-line sorafenib monotherapy achieved a durable stable response and subsequent use of sunitinib and then everolimus permitted a return to SD after disease progression. The patient experienced minimal toxicity from the regimen, suggesting that it can be safely administered to elderly patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-010-9589-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "name": "Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study", 
    "pagination": "1379-1383", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "92ba0561eb7be50dd8d3f48da2685ce1f1b7bba3a4fd5235cae2f42d5a7423e2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20593250"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-010-9589-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1030799862"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-010-9589-x", 
      "https://app.dimensions.ai/details/publication/pub.1030799862"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12032-010-9589-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-010-9589-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-010-9589-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-010-9589-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-010-9589-x'


 

This table displays all metadata directly associated to this object as RDF triples.

212 TRIPLES      21 PREDICATES      63 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-010-9589-x schema:about N04d73fd3611b427488378ff6da27a0d5
2 N073263d849c745ce97c537842e49163c
3 N0db91dbfc8c14c239d940dc58f2ee94c
4 N2a47abe7a37b4a6cb7f4806506660379
5 N2e04dc0872e7497ab6d0f1be1be5d2a3
6 N2f611d2a0a92466ab80ae6d0a3692ca1
7 N352467207f6c43b5ba5419d3314f85cd
8 N3fd68c682b8443e48472bc7833feb47a
9 N50dadc7ebcb14412a2e763e7478b226f
10 N513161e8b9904900a016e3210db98d20
11 N54a74b4f616b4636995efe2f8fce2772
12 N689a73d95a704e928a0de170255d33e1
13 N713b8bf085414fd1a793f4a83b37a1d1
14 N953cee6ca8144eee8f73c3370019de80
15 Nc02dfd1dd01f48258bfcb216ef5f4051
16 Nc0e8fbb4c9e64155a2d7861e3f9c2b0c
17 Nc7127dd8fefe45c6a64f664975688957
18 Nc7295567f4b44d9d8d0eb28941fa41eb
19 Ncd1eb5c7ffd044dd860de40da53f8b92
20 Nf2871ce2cc944abaa9d3eeb89c613e2f
21 Nffdd7cc9efb643bb92fdb1f57b21221d
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N26fb2a8a86614413a6d6e5a52a9f1d15
25 schema:citation https://doi.org/10.1002/cncr.24241
26 https://doi.org/10.1016/j.critrevonc.2008.08.002
27 https://doi.org/10.1016/j.juro.2009.02.119
28 https://doi.org/10.1016/s0140-6736(08)61039-9
29 https://doi.org/10.1056/nejmoa060655
30 https://doi.org/10.1056/nejmoa065044
31 https://doi.org/10.1093/jnci/djn319
32 https://doi.org/10.1111/j.1464-410x.2006.06015.x
33 https://doi.org/10.1200/jco.2004.07.960
34 https://doi.org/10.1200/jco.2005.23.16_suppl.3069
35 https://doi.org/10.1200/jco.2008.19.3342
36 https://doi.org/10.1200/jco.2008.19.5511
37 https://doi.org/10.1200/jco.2008.20.1293
38 schema:datePublished 2011-12
39 schema:datePublishedReg 2011-12-01
40 schema:description Long-term stabilization of advanced renal cell carcinoma (RCC) by the sequence of sorafenib monotherapy followed by sunitinib and everolimus treatments in a man with multiple metastases is reported. A 66-year-old man was diagnosed with advanced RCC in 2005. The patient initially underwent nephrectomy, but subsequently the disease metastasized to the lung, lymph nodes, and pancreas. The patient received sorafenib 400 mg bid in a clinical trial. He experienced minimal and manageable adverse events and achieved stable disease (SD), which was maintained with sorafenib therapy for nearly 3 years before the development of liver metastases. The patient was then prescribed sunitinib, with which he also experienced SD for 1.2 years until disease progression prompted the initiation of third-line everolimus therapy, resulting in SD for another 8 months. The patient lived with stabilized RCC for 4.6 years with the use of these three sequential targeted therapies. First-line sorafenib monotherapy achieved a durable stable response and subsequent use of sunitinib and then everolimus permitted a return to SD after disease progression. The patient experienced minimal toxicity from the regimen, suggesting that it can be safely administered to elderly patients.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf Nb9e7fe7aaa5b40209ba19c033d6057e9
45 Ndeb876b9be9844839b32cd28ccabee6e
46 sg:journal.1094524
47 schema:name Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study
48 schema:pagination 1379-1383
49 schema:productId N0575a66a7ce949de8ec3a6a36ac68813
50 N64fc7fee73d041ecb0355a438a1a92b7
51 Nb94c83619fe540b196f7f5c38d733311
52 Nebf892cad5424b779e89a0ecf217d165
53 Nfbabdd3fcd834eacbbf4a69770dbd49d
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030799862
55 https://doi.org/10.1007/s12032-010-9589-x
56 schema:sdDatePublished 2019-04-10T13:20
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N6ea01305ab3c4b51be935383b4d21cc2
59 schema:url http://link.springer.com/10.1007%2Fs12032-010-9589-x
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N04d73fd3611b427488378ff6da27a0d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Everolimus
65 rdf:type schema:DefinedTerm
66 N0575a66a7ce949de8ec3a6a36ac68813 schema:name dimensions_id
67 schema:value pub.1030799862
68 rdf:type schema:PropertyValue
69 N073263d849c745ce97c537842e49163c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Phenylurea Compounds
71 rdf:type schema:DefinedTerm
72 N0db91dbfc8c14c239d940dc58f2ee94c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Sirolimus
74 rdf:type schema:DefinedTerm
75 N26fb2a8a86614413a6d6e5a52a9f1d15 rdf:first sg:person.010707011202.74
76 rdf:rest N7889bdeb1e59463fa1ddd825b6a7ca09
77 N2a47abe7a37b4a6cb7f4806506660379 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Lung Neoplasms
79 rdf:type schema:DefinedTerm
80 N2e04dc0872e7497ab6d0f1be1be5d2a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Lymphatic Metastasis
82 rdf:type schema:DefinedTerm
83 N2f611d2a0a92466ab80ae6d0a3692ca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Benzenesulfonates
85 rdf:type schema:DefinedTerm
86 N352467207f6c43b5ba5419d3314f85cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Pyrroles
88 rdf:type schema:DefinedTerm
89 N3fd68c682b8443e48472bc7833feb47a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Liver Neoplasms
91 rdf:type schema:DefinedTerm
92 N50dadc7ebcb14412a2e763e7478b226f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Niacinamide
94 rdf:type schema:DefinedTerm
95 N513161e8b9904900a016e3210db98d20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Clinical Trials, Phase II as Topic
97 rdf:type schema:DefinedTerm
98 N54a74b4f616b4636995efe2f8fce2772 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Randomized Controlled Trials as Topic
100 rdf:type schema:DefinedTerm
101 N64fc7fee73d041ecb0355a438a1a92b7 schema:name pubmed_id
102 schema:value 20593250
103 rdf:type schema:PropertyValue
104 N689a73d95a704e928a0de170255d33e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Carcinoma, Renal Cell
106 rdf:type schema:DefinedTerm
107 N6ea01305ab3c4b51be935383b4d21cc2 schema:name Springer Nature - SN SciGraph project
108 rdf:type schema:Organization
109 N713b8bf085414fd1a793f4a83b37a1d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N7889bdeb1e59463fa1ddd825b6a7ca09 rdf:first sg:person.01174264563.01
113 rdf:rest Nb2dcba31627f4130a89b63a8ad65eb21
114 N953cee6ca8144eee8f73c3370019de80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Kidney Neoplasms
116 rdf:type schema:DefinedTerm
117 Nb2dcba31627f4130a89b63a8ad65eb21 rdf:first sg:person.01304252172.82
118 rdf:rest rdf:nil
119 Nb94c83619fe540b196f7f5c38d733311 schema:name doi
120 schema:value 10.1007/s12032-010-9589-x
121 rdf:type schema:PropertyValue
122 Nb9e7fe7aaa5b40209ba19c033d6057e9 schema:issueNumber 4
123 rdf:type schema:PublicationIssue
124 Nc02dfd1dd01f48258bfcb216ef5f4051 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Indoles
126 rdf:type schema:DefinedTerm
127 Nc0e8fbb4c9e64155a2d7861e3f9c2b0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Pancreatic Neoplasms
129 rdf:type schema:DefinedTerm
130 Nc7127dd8fefe45c6a64f664975688957 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antineoplastic Agents
132 rdf:type schema:DefinedTerm
133 Nc7295567f4b44d9d8d0eb28941fa41eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Pyridines
135 rdf:type schema:DefinedTerm
136 Ncd1eb5c7ffd044dd860de40da53f8b92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Male
138 rdf:type schema:DefinedTerm
139 Ndeb876b9be9844839b32cd28ccabee6e schema:volumeNumber 28
140 rdf:type schema:PublicationVolume
141 Nebf892cad5424b779e89a0ecf217d165 schema:name readcube_id
142 schema:value 92ba0561eb7be50dd8d3f48da2685ce1f1b7bba3a4fd5235cae2f42d5a7423e2
143 rdf:type schema:PropertyValue
144 Nf2871ce2cc944abaa9d3eeb89c613e2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Combined Chemotherapy Protocols
146 rdf:type schema:DefinedTerm
147 Nfbabdd3fcd834eacbbf4a69770dbd49d schema:name nlm_unique_id
148 schema:value 9435512
149 rdf:type schema:PropertyValue
150 Nffdd7cc9efb643bb92fdb1f57b21221d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged
152 rdf:type schema:DefinedTerm
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:journal.1094524 schema:issn 1357-0560
160 1559-131X
161 schema:name Medical Oncology
162 rdf:type schema:Periodical
163 sg:person.010707011202.74 schema:affiliation https://www.grid.ac/institutes/grid.5802.f
164 schema:familyName Beck
165 schema:givenName Joachim
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010707011202.74
167 rdf:type schema:Person
168 sg:person.01174264563.01 schema:affiliation https://www.grid.ac/institutes/grid.411142.3
169 schema:familyName Bellmunt
170 schema:givenName Joaquim
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174264563.01
172 rdf:type schema:Person
173 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
174 schema:familyName Escudier
175 schema:givenName Bernard
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
177 rdf:type schema:Person
178 https://doi.org/10.1002/cncr.24241 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015298784
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1016/j.critrevonc.2008.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041881420
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/j.juro.2009.02.119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001110310
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/jnci/djn319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015009768
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1111/j.1464-410x.2006.06015.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002209252
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1200/jco.2004.07.960 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015578863
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1200/jco.2005.23.16_suppl.3069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079369106
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1200/jco.2008.19.3342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015052000
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1200/jco.2008.19.5511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017988502
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1200/jco.2008.20.1293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013684571
203 rdf:type schema:CreativeWork
204 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
205 schema:name Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France
206 rdf:type schema:Organization
207 https://www.grid.ac/institutes/grid.411142.3 schema:alternateName Hospital Del Mar
208 schema:name Department of Oncology, University Hospital del Mar-IMIM, 08003, Barcelona, Spain
209 rdf:type schema:Organization
210 https://www.grid.ac/institutes/grid.5802.f schema:alternateName Johannes Gutenberg University of Mainz
211 schema:name Internal Department III, Johannes-Gutenberg-University, Langenbeckstr. 1, 55131, Mainz, Germany
212 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...